| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/03/2004 | EP1393736A1 Use of ginkgo biloba terpene free flavonoidic extract for oral hygiene, and composition containing such extract |
| 03/03/2004 | EP1393735A2 Chemotherapeutic compositions |
| 03/03/2004 | EP1393734A1 Drugs for intestinal diseases |
| 03/03/2004 | EP1393733A1 Flavonoid-derivate for the treatment of eczema |
| 03/03/2004 | EP1393732A1 Minoxidil-containing liquid composition |
| 03/03/2004 | EP1393731A1 Novel use of arylethenesulfonamide derivative |
| 03/03/2004 | EP1393730A2 Combination chemotherapy involving topotecan and a platinum coordination compound |
| 03/03/2004 | EP1393729A2 Combination chemotherapy involving topotecan and a platinum coordination compound |
| 03/03/2004 | EP1393728A1 Inverse agonists acting at virus-encoded G protein-coupled receptors |
| 03/03/2004 | EP1393727A1 Remedial agent for myelopathic disease |
| 03/03/2004 | EP1393726A1 Compositions for improving mental concentration |
| 03/03/2004 | EP1393725A1 Compositions for ameliorating attention-deficient/hyperactivity disorder |
| 03/03/2004 | EP1393724A2 Novel formulations for the transdermal administration of fluoxetine |
| 03/03/2004 | EP1393723A2 Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces |
| 03/03/2004 | EP1393722A2 Use of angiotensin II subtype 1 (AT1) antagonists for the manufacture of a medicament in the treatment of premenstrual syndrome |
| 03/03/2004 | EP1393721A1 Dosage form of powder agglomerates |
| 03/03/2004 | EP1393720A1 Vesicle-encapsulated corticosteroids for treatment of cancer |
| 03/03/2004 | EP1393719A1 Camptothecin-carboxylate formulations |
| 03/03/2004 | EP1393713A1 Liquid concentrate for the preservation of cosmetic and pharmaceutical products |
| 03/03/2004 | EP1393637A1 Agent for sustaining concentration and attentiveness and food and drink containing the agent |
| 03/03/2004 | EP1393633A1 Food or veterinary composition for domestic carnivores containing free tyrosine |
| 03/03/2004 | EP1393518A2 Arylsulfatase-inhibitors in deodorants and antiperspirants |
| 03/03/2004 | EP1393277A1 Use of nfkb inhibitors to treat dry eye disorders |
| 03/03/2004 | EP1393077A2 Method for identifying ligands for g protein coupled receptors |
| 03/03/2004 | EP1392867A2 Antisense modulation of ptp1b expression |
| 03/03/2004 | EP1392845A2 A g-protein coupled receptor and uses therefor |
| 03/03/2004 | EP1392829A2 Compositions and methods relating to lung specific genes and proteins |
| 03/03/2004 | EP1392823A2 Desaturase genes and uses thereof |
| 03/03/2004 | EP1392816A1 Production of bioavailable folic acid |
| 03/03/2004 | EP1392730A2 Transcriptional regulator of genes involved in the control of cell growth or cell proliferation. use of said regulator as a therapeutic or diagnostic agent |
| 03/03/2004 | EP1392714A1 Steroids as agonists for fxr |
| 03/03/2004 | EP1392713A2 Liver x receptor agonists |
| 03/03/2004 | EP1392704A1 Cephem compounds |
| 03/03/2004 | EP1392702A1 Compounds and methods for inhibiting mrp1 |
| 03/03/2004 | EP1392701A1 Compounds and pharmaceutical compositions for inhibiting mrp1 |
| 03/03/2004 | EP1392700A1 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta(a)naphthalene |
| 03/03/2004 | EP1392699A1 6h-oxazolo 4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 03/03/2004 | EP1392697A1 Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-dioxino 2,3-f]quinoline |
| 03/03/2004 | EP1392696A1 Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro 2,3-b]quinolin-4-yl)-2-(2- oxopyrrolidin -1 -yl)acetamide |
| 03/03/2004 | EP1392695A2 Triazolopyrimidines |
| 03/03/2004 | EP1392694A1 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo[2,3]pyrimidine derivatives as protein kinases inhibitors |
| 03/03/2004 | EP1392692A1 (oxo-pyrazolo 1,5a]pyrimidin-2-yl)alkyl-carboxamides |
| 03/03/2004 | EP1392691A1 ANTIFUNGAL 4-SUBSTITUTED 5,6-DIHYDRO-4 u H /u -PYRROLO 1,2-A] 1,4]BENZODIAZEPINES |
| 03/03/2004 | EP1392690A2 Novel processes for the preparation of adenosine compounds and intermediates thereto |
| 03/03/2004 | EP1392689A1 Tri- and tetraaza-acenaphthylen derivatives as crf receptor antagonists |
| 03/03/2004 | EP1392688A1 Pyrazino[1',2':1,6]pyrido[3,4-b]indole1,4-dione derivatives |
| 03/03/2004 | EP1392687A1 1,3,8-triazaspiro[4,5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
| 03/03/2004 | EP1392686A1 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials |
| 03/03/2004 | EP1392685A1 Tropane alkaloid multidrug resistance inhibitors from erythroxylum pervillei and use of the same |
| 03/03/2004 | EP1392684A1 Thiazole compounds useful as inhibitors of protein kinases |
| 03/03/2004 | EP1392683A1 SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF |
| 03/03/2004 | EP1392682A2 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 03/03/2004 | EP1392681A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| 03/03/2004 | EP1392680A2 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
| 03/03/2004 | EP1392679A1 Novel 1-amidomethylcarbonyl-piperidine derivatives, method and intermediate products for the production thereof and medicament containing said compounds |
| 03/03/2004 | EP1392677A2 Chiral broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions |
| 03/03/2004 | EP1392676A2 Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands |
| 03/03/2004 | EP1392674A1 Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors |
| 03/03/2004 | EP1392670A1 Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives |
| 03/03/2004 | EP1392669A1 Chromatographic separation method of paclitaxel and cephalomannin |
| 03/03/2004 | EP1392666A1 Biologically active methylene blue derivatives |
| 03/03/2004 | EP1392665A1 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases |
| 03/03/2004 | EP1392664A1 Epothilone derivatives |
| 03/03/2004 | EP1392663A2 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof |
| 03/03/2004 | EP1392662A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| 03/03/2004 | EP1392661A1 Diarylurea derivatives useful as anti-inflammatory agents |
| 03/03/2004 | EP1392658A1 Novel fused indazoles and indoles and their use for the treatment of glaucoma |
| 03/03/2004 | EP1392657A2 Protease inhibitors |
| 03/03/2004 | EP1392656A2 Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors |
| 03/03/2004 | EP1392655A2 Potassium channel openers |
| 03/03/2004 | EP1392651A1 Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists |
| 03/03/2004 | EP1392648A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors |
| 03/03/2004 | EP1392645A2 Aza hydroxylated ethyl amine compounds |
| 03/03/2004 | EP1392644A1 Cinnamide derivatives as kcnq potassium channel modulators |
| 03/03/2004 | EP1392643A2 Trisubstituted-n- (1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors |
| 03/03/2004 | EP1392642A2 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 03/03/2004 | EP1392641A1 Substituted cyclohexane-1,4-diamine derivatives |
| 03/03/2004 | EP1392639A1 Pyruvate derivatives |
| 03/03/2004 | EP1392637A2 Modulators of peroxisome proliferator activated receptors |
| 03/03/2004 | EP1392623A1 Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsatruated fatty acids from microbes, genetically modified plant seeds and marine organisms |
| 03/03/2004 | EP1392399A1 Use and compositions of antiprogestins for treatment of prostate diseases |
| 03/03/2004 | EP1392389A2 Microprojection array having a beneficial agent containing coating |
| 03/03/2004 | EP1392381A1 An aerosol forming device for use in inhalation therapy |
| 03/03/2004 | EP1392375A2 Composition and use of substances for stabilising amino acids containing sulphur |
| 03/03/2004 | EP1392363A2 Compositions and uses of mglur5 antagonists |
| 03/03/2004 | EP1392355A1 Use of proteasome inhibitors to treat dry eye disorders |
| 03/03/2004 | EP1392352A1 Use of an antioxidant for treating and/or preventing surface ocular disorders |
| 03/03/2004 | EP1392348A1 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
| 03/03/2004 | EP1392340A2 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof |
| 03/03/2004 | EP1392338A1 Herbal drug composition for cartilage protection |
| 03/03/2004 | EP1392337A1 Pharmaceutical formulation consisting of a plant dry extract with a calcium coating |
| 03/03/2004 | EP1392336A1 Korean acanthopanax senticosus extract, protein extract, crude protein-polysaccharide which were extracted from korean acanthopanax senticosus, and immunoregulating compositions comprising the same and use thereof |
| 03/03/2004 | EP1392335A1 Pharmaceutical and/or cosmetic compositions for the treatment of localised adiposities and cellulite |
| 03/03/2004 | EP1392334A2 Therapeutic methods using herbal compositions |
| 03/03/2004 | EP1392331A1 Method for lowering serum glucose |
| 03/03/2004 | EP1392330A1 Use of lps for treating intestinal inflammation processes |
| 03/03/2004 | EP1392329A1 Use of sulodexide for the treatment of inflammatory bowel disease |
| 03/03/2004 | EP1392328A2 Cancer therapy |
| 03/03/2004 | EP1392327A2 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases |
| 03/03/2004 | EP1392326A1 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |